A new Alzheimer’s drug hitting the market is the first with clear-cut evidence that it can at least modestly slow the disease. But it's only for early-stage patients, requires IV doses every two weeks, comes with safety concerns and costs $26,500 a year.
In Eisai’s 18-month study of nearly 1,800 people, Leqembi appeared to delay early-stage patients from getting worse by about five months.
Other experts say slowing the disease early on, when people still function well, is important even if it’s not that easy to spot. While the brain swelling and bleeds may cause only minimal symptoms such as dizziness and vision problems, they occasionally can be severe — and several Leqembi users have died while taking the drug, including two who were on blood-thinning medications.Eisai has said the deaths can’t be attributed to its Alzheimer’s drug.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
EXPLAINER: New drug slows Alzheimer's but comes with caveatsA new Alzheimer’s drug is hitting the market with experts voicing a lot of caution
Read more »
EXPLAINER: New Details and Next Steps in Case of Slain Idaho StudentsIt’s been weeks since four University of Idaho students were stabbed to death in their beds, and now some of the mystery surrounding the case may soon fall away.
Read more »
New Alzheimer’s Drug Approved by FDA, Promises to Slow DiseaseBreaking: A new Alzheimer's drug has been cleared for use in the U.S. Doctors say it could transform the way the disease is treated.
Read more »
FDA approves new Alzheimer’s drug that appears to slow progression of diseaseBREAKING: FDA approves Alzheimer’s drug shown in clinical trials to slow cognitive decline in patients in the early stages of the illness.
Read more »
FDA grants accelerated approval to Alzheimer's drug for people with early stage diseaseBREAKING: FDA grants accelerated approval to new Alzheimer's treatment that can slow cognitive decline in people with early stages of the disease.
Read more »
FDA approves new experimental Alzheimer's drugThe Food and Drug Administration granted accelerated approval for Eisai and Biogen's experimental Alzheimer's drug, lecanemab, on Friday, offering a new treatment option for the more than 6.5 million people with Alzheimer's in the United States.
Read more »